196 related articles for article (PubMed ID: 28760780)
1. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-
Brown BM; Shim H; Zhang M; Yarov-Yarovoy V; Wulff H
Mol Pharmacol; 2017 Oct; 92(4):469-480. PubMed ID: 28760780
[TBL] [Abstract][Full Text] [Related]
2. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Coleman N; Brown BM; Oliván-Viguera A; Singh V; Olmstead MM; Valero MS; Köhler R; Wulff H
Mol Pharmacol; 2014 Sep; 86(3):342-57. PubMed ID: 24958817
[TBL] [Abstract][Full Text] [Related]
3. The Trials and Tribulations of Structure Assisted Design of K
Shim H; Brown BM; Singh L; Singh V; Fettinger JC; Yarov-Yarovoy V; Wulff H
Front Pharmacol; 2019; 10():972. PubMed ID: 31616290
[TBL] [Abstract][Full Text] [Related]
4. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the KCa3.1 channel-calmodulin interactions to the regulation of the KCa3.1 gating process.
Morales P; Garneau L; Klein H; Lavoie MF; Parent L; Sauvé R
J Gen Physiol; 2013 Jul; 142(1):37-60. PubMed ID: 23797421
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
8. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Oliván-Viguera A; Valero MS; Coleman N; Brown BM; Laría C; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Wulff H; Badorrey R; Köhler R
Mol Pharmacol; 2015 Feb; 87(2):338-48. PubMed ID: 25468883
[TBL] [Abstract][Full Text] [Related]
9. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
[TBL] [Abstract][Full Text] [Related]
11. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
12. Aromatic-aromatic interactions between residues in KCa3.1 pore helix and S5 transmembrane segment control the channel gating process.
Garneau L; Klein H; Lavoie MF; Brochiero E; Parent L; Sauvé R
J Gen Physiol; 2014 Feb; 143(2):289-307. PubMed ID: 24470490
[TBL] [Abstract][Full Text] [Related]
13. SKA-31, an activator of endothelial Ca
Khaddaj-Mallat R; Mathew John C; Braun AP
Eur J Pharmacol; 2018 Jul; 831():60-67. PubMed ID: 29753043
[TBL] [Abstract][Full Text] [Related]
14. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice.
Radtke J; Schmidt K; Wulff H; Köhler R; de Wit C
Br J Pharmacol; 2013 Sep; 170(2):293-303. PubMed ID: 23734697
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the C-terminal four-helix bundle of the potassium channel KCa3.1.
Ji T; Corbalán-García S; Hubbard SR
PLoS One; 2018; 13(6):e0199942. PubMed ID: 29953543
[TBL] [Abstract][Full Text] [Related]
16. Role of S3 and S4 transmembrane domain charged amino acids in channel biogenesis and gating of KCa2.3 and KCa3.1.
Gao Y; Chotoo CK; Balut CM; Sun F; Bailey MA; Devor DC
J Biol Chem; 2008 Apr; 283(14):9049-59. PubMed ID: 18227067
[TBL] [Abstract][Full Text] [Related]
17. Are there superagonists for calcium-activated potassium channels?
Brown BM; Shim H; Wulff H
Channels (Austin); 2017 Nov; 11(6):504-506. PubMed ID: 28876978
[No Abstract] [Full Text] [Related]
18. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1.
Srivastava S; Choudhury P; Li Z; Liu G; Nadkarni V; Ko K; Coetzee WA; Skolnik EY
Mol Biol Cell; 2006 Jan; 17(1):146-54. PubMed ID: 16251351
[TBL] [Abstract][Full Text] [Related]
19. A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model.
Mishra RC; Mitchell JR; Gibbons-Kroeker C; Wulff H; Belenkie I; Tyberg JV; Braun AP
Vascul Pharmacol; 2016 Apr; 79():24-31. PubMed ID: 26239885
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
